期刊
MOLECULAR THERAPY
卷 26, 期 6, 页码 1552-1567出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2018.02.022
关键词
-
资金
- Fondo de Investigacion SanitariaInstituto de Salud Carlos III grants
- CIBERNED - ERDF (European Regional Development Fund) A way to build Europe [PI13/01897, CP11/00229, PI15/01937]
- CIBERSAM - ERDF (European Regional Development Fund) A way to build Europe [PI13/01390, SAF2016-75797-R]
- AGAUR-GRC grant [2014-SGR-1609]
- Fondo de Investigacion SanitariaInstituto de Salud Carlos III (PFIS) [FI14/00613]
The possible implication of transcription factor EB (TFEB) as a therapeutic target in Parkinson's disease has gained momentum since it was discovered that TFEB controls lysosomal biogenesis and autophagy and that its activation might counteract lysosomal impairment and protein aggregation. However, the majority of putative direct targets of TFEB described to date is linked to a range of biological processes that are not related to the lysosomal-autophagic system. Here, we assessed the effect of overexpressing TFEB with an adeno-associated viral vector in mouse substantia nigra dopaminergic neurons. We demonstrate that TFEB overexpression drives a previously unknown bona fide neurotrophic effect, giving rise to cell growth, higher tyrosine hydroxylase levels, and increased dopamine release in the striatum. TFEB overexpression induces the activation of the mitogen-activated protein kinase 1/3 (MAPK1/3) and AKT pro-survival pathways, phosphorylation of mTORC1 effectors 4E-binding protein 1 (4E-BP1) and S6 kinase B1 (S6K1), and increased protein synthesis. We show that TFEB overexpression prevents dopaminergic cell loss and counteracts atrophy and the associated protein synthesis decline in the MPTP mouse model of Parkinson's disease. Our results suggest that increasing TFEB activity might prevent neuronal death and restore neuronal function in Parkinson's disease and other neurodegenerative diseases through different mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据